about
Tripartite motif containing protein 27 negatively regulates CD4 T cells by ubiquitinating and inhibiting the class II PI3K-C2βRoles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implicationsPhosphoinositides: tiny lipids with giant impact on cell regulationPAK4 interacts with p85 alpha: implications for pancreatic cancer cell migrationSpecific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growthExpression of the RAE-1 family of stimulatory NK-cell ligands requires activation of the PI3K pathway during viral infection and transformation.Anti-IL-2 treatment impairs the expansion of T(reg) cell population during acute malaria and enhances the Th1 cell response at the chronic diseaseProton-assisted amino acid transporter PAT1 complexes with Rag GTPases and activates TORC1 on late endosomal and lysosomal membranes.Functional redundancy of class I phosphoinositide 3-kinase (PI3K) isoforms in signaling growth factor-mediated human neutrophil survivalNovel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma.Quantification of PtdInsP3 molecular species in cells and tissues by mass spectrometry.The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic DiseasesVS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancerPhosphatidylinositol 3-phosphates-at the interface between cell signalling and membrane traffic.Phosphoinositide 3-kinase p110δ promotes lumen formation through the enhancement of apico-basal polarity and basal membrane organization.Classes of phosphoinositide 3-kinases at a glance.Abi1, a critical molecule coordinating actin cytoskeleton reorganization with PI-3 kinase and growth signaling.Inhibition of p110δ PI3K prevents inflammatory response and restenosis after artery injury.Phosphoinositide 3-Kinase-Dependent Signalling Pathways in Cutaneous Squamous Cell Carcinomas.PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α.Novel roles for class II Phosphoinositide 3-Kinase C2β in signalling pathways involved in prostate cancer cell invasion.Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype.MCP-1 impacts RCT by repressing ABCA1, ABCG1, and SR-BI through PI3K/Akt posttranslational regulation in HepG2 cells.Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence.Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS.Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ.PIK3CA mutant tumors depend on oxoglutarate dehydrogenase.Identification of a Potent Phosphoinositide 3-Kinase Pan Inhibitor Displaying a Strategic Carboxylic Acid Group and Development of Its Prodrugs.Cell biology. Where is PTEN?
P2860
Q24298688-E1A5C21E-CB51-420D-A18E-B270654664FCQ27009016-46B25CEF-1F90-409D-A81C-3C788D346E38Q27012953-BBEE2FFD-D239-4442-8871-DD94C16DA33FQ30838867-4EA85800-D0A4-448C-9378-81D3CA34C149Q33631442-07010FC8-26B4-4E86-A072-4C1B88E0F145Q34037679-5F8D786C-FA7E-41B9-BD26-F1341BAA015DQ34137399-2E4F999B-3B45-4BE8-A4AA-FEB2AE7DEEEDQ34264817-897D41E6-DA62-4C78-B4A5-E09E8807E292Q34430434-AD043029-0A70-45A2-A89E-07D12444C7B2Q34442835-3401CE5B-8CFE-4143-8F2F-3FB3063464C1Q36285541-D4CF7E03-3ED0-4663-AF88-06392518B5C3Q36286414-915E5A98-0D70-4A12-9189-A1BDC866CA6DQ36656352-999CF262-7453-4661-8CE6-E8786B1A9288Q36712621-76DFA73A-8933-4E30-B7E4-EA4D6F951346Q37391638-A76EE79E-E649-4E3F-A2C4-B460CECD61E6Q37608715-E5FC97D2-FD8E-466F-B6F4-1AB6486BB3ECQ38012229-CE27F1A0-D063-4259-96B4-F0E8B478AB18Q38603120-9868AA2E-67DA-403D-A28D-F69F06498155Q38684394-5B7A5006-C9A5-48F8-B867-614E21347918Q38718336-5783F396-EC6F-4B6B-A757-F986503CC25AQ38785807-C16A2268-D671-40AB-A258-C0AEF21EFC77Q39380262-CC7963E7-DBBE-4F4F-883D-A2F0735896DCQ39741605-F806673E-65B1-4D79-9AF9-65F7EB85D3A9Q42178287-A946E056-C510-4ACB-8B22-37E670423A87Q42330188-7A07BEA1-A087-4D35-BB15-6F62EDBB6321Q42378867-A9FAA245-440B-497F-BD56-58F9DB91EE1BQ42580090-85F89E56-897A-45B2-AD92-98F187E593C1Q47137924-FC0AC66D-5318-4F35-A02F-580C27FA3D5CQ47931091-63AD6A34-C53D-4E75-A3D0-9ED63ED74BDC
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
PI3K: from the bench to the clinic and back.
@ast
PI3K: from the bench to the clinic and back.
@en
PI3K: from the bench to the clinic and back.
@nl
type
label
PI3K: from the bench to the clinic and back.
@ast
PI3K: from the bench to the clinic and back.
@en
PI3K: from the bench to the clinic and back.
@nl
prefLabel
PI3K: from the bench to the clinic and back.
@ast
PI3K: from the bench to the clinic and back.
@en
PI3K: from the bench to the clinic and back.
@nl
P2860
P356
P1476
PI3K: from the bench to the clinic and back.
@en
P2093
Bart Vanhaesebroeck
Christian Rommel
P2860
P356
10.1007/82_2010_65
P50
P577
2010-01-01T00:00:00Z